Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Xolair (omalizumab) is a monoclonal antibody that binds immunoglobulin E (IgE) to reduce chronic hives (chronic idiopathic urticaria) and is generally well tolerated. Common side effects in 1–10% of patients include injection site reactions, headache, fatigue, and mild respiratory symptoms. Rare but serious risks, such as anaphylaxis, are tracked through ongoing safety audits and post-marketing surveillance.
Key considerations when weighing benefits and risks include monitoring protocols after each injection, individualized risk mitigation strategies, and recognizing when to seek emergency care for signs like throat tightness, dizziness, or severe swelling.
Because chronic hives, fatigue, and respiratory symptoms can overlap with many other conditions, understanding what's driving your symptoms is a critical first step before starting or continuing treatment. Take a free, instant, online symptom check to clarify possible causes, identify red flags, and confidently navigate your next steps with your healthcare provider.
Reviewed for medical accuracy: 07/10/2026
Xolair (omalizumab) is a widely used treatment for chronic spontaneous urticaria (chronic hives) in adults and adolescents. It works by binding to immunoglobulin E (IgE) antibodies, reducing the allergic response that drives hives. While many patients find significant relief, it's important to understand the potential side effects of Xolair for chronic hives and how safety authorities monitor its use.
Most side effects of Xolair for chronic hives are mild to moderate and often improve over time:
If you notice these effects, you or your care team can often manage them with simple measures—ice packs for injection sites, over-the-counter pain relievers, rest, or hydration.
A small percentage of people may experience more pronounced reactions:
While these aren't usually life threatening, let your doctor know if they persist or worsen.
Though uncommon, certain side effects of Xolair for chronic hives can be severe:
Clinical studies suggest anaphylaxis occurs in about 0.1–0.2% of patients, typically within two hours of injection. For this reason:
Regulatory agencies and manufacturers continuously track adverse event reports:
These audits can prompt updated warnings, new risk-mitigation strategies, or additional patient guidance.
To reduce the likelihood and impact of side effects:
If you're experiencing symptoms and need help deciding whether they require urgent medical attention, you can use Ubie's free AI symptom checker to get immediate guidance on your next steps.
Many patients with chronic hives experience a substantial drop in flare-ups and improved quality of life with Xolair. To maintain that balance:
Consider consulting an allergist or immunologist if:
Understanding the side effects of Xolair for chronic hives helps you make informed decisions and catch any issues early. While most reactions are mild, knowing how to respond to serious symptoms ensures your safety.
Always speak to a doctor about any concerning or life-threatening symptoms. If you're uncertain about what your symptoms mean or when to seek care, Ubie's AI-powered symptom assessment tool can provide personalized insights in just minutes to help guide your next steps.
Your health is a partnership—stay proactive, ask questions, and keep your medical team in the loop.
(References)
* Tharayil, J., et al. "Long-term safety of omalizumab in patients with chronic spontaneous urticaria: a 5-year study." *Journal of the American Academy of Dermatology*, vol. 88, no. 5, 2023, pp. 1021-1029. DOI: 10.1016/j.jaad.2022.11.025. PMID: 36470438.
* Zhao, Z., et al. "Safety and tolerability of omalizumab in chronic spontaneous urticaria: a systematic review and meta-analysis." *Journal of Dermatological Treatment*, vol. 31, no. 6, 2020, pp. 629-637. DOI: 10.1080/09546634.2019.1627993. PMID: 31154865.
* Han, S., et al. "Safety profile of omalizumab in chronic spontaneous urticaria: a real-world study and literature review." *Journal of Korean Medical Science*, vol. 37, no. 28, 2022, e223. DOI: 10.3346/jkms.2022.37.e223. PMID: 35848133.
* Zhou, Q., et al. "Safety of omalizumab in the treatment of chronic spontaneous urticaria: A systematic review and meta-analysis." *Clinical & Experimental Allergy*, vol. 50, no. 5, 2020, pp. 544-555. DOI: 10.1111/cea.13567. PMID: 31922435.
* Al-Ani, N., et al. "Adverse Events in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab: A Retrospective Analysis." *Clinical Reviews in Allergy & Immunology*, vol. 60, no. 2, 2021, pp. 248-257. DOI: 10.1007/s12016-020-08795-9. PMID: 32909247.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.